TrialThe journal of headache and pain2022

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).

Karissa Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.